HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission
source: pixabay.com

HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission

In January 2024, the FDA approved Hyqvia (Immune Globulin Infusion 10% [Human]) as a maintenance therapy for adults living with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder.  As…

Continue Reading HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission
Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial
source: shutterstock.com

Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial

According to a story from Business Wire, the pharmaceutical company Takeda recently presented results from its phase 3 clinical trial evaluating HYQVIA (Human Immune Globulin Infusion 10% with Recombinant Human…

Continue Reading Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial
Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP

  In June 2023, the U.S. Food and Drug Administration (FDA) approved the use of VYVGART Hytrulo for people living with generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disease…

Continue Reading Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP
Being an Olympic Swimming Legend Doesn’t Ease the Burden of Chronic Inflammatory Demyelinating Polyneuropathy
source: pixabay.com

Being an Olympic Swimming Legend Doesn’t Ease the Burden of Chronic Inflammatory Demyelinating Polyneuropathy

  After winning the 1998 100m butterfly in Perth, breaking a world record, winning 54 international medals, and becoming the Swimming Hall of Fame inductee in 2022, Michael Klim appeared…

Continue Reading Being an Olympic Swimming Legend Doesn’t Ease the Burden of Chronic Inflammatory Demyelinating Polyneuropathy
May is GBS and CIDP Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

May is GBS and CIDP Awareness Month: Spreading Rare Disease Awareness

The month of May is recognized as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) awareness month, a time set aside to spread awareness about these rare conditions among…

Continue Reading May is GBS and CIDP Awareness Month: Spreading Rare Disease Awareness
Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
source: pixabay.com

Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

The FDA has just provided Orphan Drug Designation to Hizentra for the treatment of adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIPD). This is a maintenance therapy which works to…

Continue Reading Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Webinar: CIDP Patient Speaker Program

  • Post author:
  • Post category:

Speakers: Elizabeth Thirtyacre Carla Duff, ANP To register for this webinar, click here. To read more about Webinar Wednesdays, click here.    Acknowledgment: This event post is sponsored by CSL Behring and is…

Continue Reading Webinar: CIDP Patient Speaker Program